Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | CASP1 | P29466 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | CASP7 | P55210 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433473 | 1.00 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1914142 | 1.00 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL29941043 | 0.99 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL29940884 | 0.99 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2036328 | 0.91 | ADK (1.00) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2035229 | 0.91 | ADK (0.84) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8267958 | 0.91 | ADK (0.83) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8193961 | 0.90 | ADK (0.98) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2037666 | 0.90 | ADK (0.82) | ADKKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8258006 | 0.90 | ADK (0.81) | ADKKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250346631-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4623925-A2 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250136990-A1 | ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE | NEUMIRNA THERAPEUTICS APS (DK) | 2025-05-01 | — | — | US | disclosed |
| US-12258425-B2 | Peptide compositions and methods of use | ONL THERAPEUTICS, INC. | 2025-03-25 | — | — | US | disclosed |
| US-12208140-B2 | Targeted delivery to beta cells | THE BROAD INSTITUTE, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240240188-A1 | ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE | NEUMIRNA THERAPEUTICS APS (DK) | 2024-07-18 | — | — | US | disclosed |
| US-20220323468-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR THE TREATMENT/PREVENTION OF LIVER DISEASE | UNIVERSITY OF SOUTH ALABAMA | 2022-10-13 | — | — | US | disclosed |
| US-20220296623-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING OR PREVENTING KIDNEY DISEASE | UNIVERSITY OF SOUTH ALABAMA | 2022-09-22 | — | — | US | disclosed |
| WO-2022187437-A1 | COMPOSITIONS AND METHODS FOR MONITORING ENPP1 ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220233565-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING/PREVENTING SKELETAL MUSCLE DISEASE | NESTLE SA (CH) | 2022-07-28 | — | — | US | disclosed |
| EP-3997981-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | Onl Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3980027-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR THE TREATMENT/PREVENTION OF LIVER DISEASE | Société des Produits Nestlé S.A. (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3980028-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING/PREVENTING SKELETAL MUSCLE DISEASE | Société des Produits Nestlé S.A. (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3980026-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING OR PREVENTING KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2022-04-13 | — | — | EP | disclosed |
| US-20220087987-A1 | A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR | NATIONAL CANCER CENTER (JP) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346631-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | VIP, TNFSF10, IAPP | ADK 4022/4885KDM4E 4831/4885MEN1 3692/4885 |
| US-20220296623-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING OR PREVENTING KIDNEY DISEASE | NNT, NADK, NAMPT | ADK 199/4885KDM4E 1206/4885MEN1 2739/4885 |
| US-20220233565-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING/PREVENTING SKELETAL MUSCLE DISEASE | SIRT1, NAMPT, NNT | ADK 977/4885KDM4E 925/4885MEN1 3677/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | ADK 4629/4885KDM4E 1927/4885MEN1 3789/4885 |
| US-12208140-B2 | Targeted delivery to beta cells | IAPP, ZFR, ZC3H11A | ADK 2148/4885KDM4E 1462/4885MEN1 2406/4885 |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | ADK 2148/4885KDM4E 1462/4885MEN1 2406/4885 |
| US-12258425-B2 | Peptide compositions and methods of use | VIP, TNFSF10, IAPP | ADK 4143/4885KDM4E 4836/4885MEN1 3610/4885 |
| US-20220323468-A1 | REDUCED NICOTINAMIDERIBOSIDES FOR THE TREATMENT/PREVENTION OF LIVER DISEASE | NNT, NAMPT, NNMT | ADK 553/4885KDM4E 1230/4885MEN1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.